



## Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

August 7, 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 7, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40<sup>th</sup> Annual Growth Conference on August 13, 2020 at 3:00pm ET.

A live audio webcast and an archive of the presentation will be available in the Investors & Media section of the company website at [ir.mirumpharma.com](http://ir.mirumpharma.com).

### About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit [mirumpharma.com](http://mirumpharma.com). Follow Mirum on [Twitter](#), [Facebook](#) and [LinkedIn](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20200807005365/en/>

Investor contact:

Ian Clements, Ph.D.

[ir@mirumpharma.com](mailto:ir@mirumpharma.com)

Media contact:

Erin Murphy

[media@mirumpharma.com](mailto:media@mirumpharma.com)

Source: Mirum Pharmaceuticals, Inc.